Showing 2 of 10 years of data. Sign up free for 5 years of history.
View Plans2-year trend showing gross, operating, and net profit margins
Jyothy Laboratories Limited's net profit margin of 11.1% in FY2026 reflects moderate profitability, with operating margin at 15.1% and gross margin at 48.1%.
In FY 2026, Jyothy Laboratories Limited posted a gross margin of 48.1%, an operating margin of 15.1%, a net margin of 11.1%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Jyothy Laboratories Limited's revenue grew 3.8% to 30.12B in FY2026, but net profit declined 10.0% to 3.33B — indicating margin compression.
In FY 2026, Jyothy Laboratories Limited's revenue grew by 3.8% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Jyothy Laboratories Limited's ROE of 21.0% in FY2026 indicates excellent capital efficiency.
In FY 2026, Jyothy Laboratories Limited reported an ROE of 21.0%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Jyothy Laboratories Limited's FCF/NI ratio of 1.04x in FY2026 indicates solid earnings quality with FCF tracking net income.
In FY 2026, Jyothy Laboratories Limited's free cash flow exceeded net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Jyothy Laboratories Limited's OCF/NI ratio of 1.24x in FY2026 indicates sound cash management with earnings well-backed by cash.
In FY 2026, Jyothy Laboratories Limited's operating cash flow exceeded net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Jyothy Laboratories Limited's current ratio of 2.68x in FY2026 indicates healthy short-term liquidity.
In FY 2026, Jyothy Laboratories Limited reported a current ratio of 2.68. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Jyothy Laboratories Limited's interest coverage ratio of 91.4x in FY2026 indicates comfortable debt servicing capacity.
In FY 2026, Jyothy Laboratories Limited reported an interest coverage ratio of 91.4x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Jyothy Laboratories Limited's debt-to-equity ratio of 0.03x in FY2026 reflects a conservative, low-leverage capital structure.
In FY 2026, Jyothy Laboratories Limited reported a debt-to-equity ratio of 0.03. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Jyothy Laboratories Limited's debt decreased 15.8% YoY in FY2026 — positive deleveraging improves financial flexibility.
In FY 2026, Jyothy Laboratories Limited's total debt decreased by 15.8% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Jyothy Laboratories Limited's diluted shares increased 0.1% YoY in FY2026 — share dilution.
Over 2 years (FY2025–FY2026), diluted shares increased 0.1% from 367.05M to 367.39M, indicating cumulative dilution.
In FY 2026, Jyothy Laboratories Limited's diluted shares increased by 0.1% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2026